$6.90
56.46% yesterday
NYSE, Oct 03, 10:20 pm CET
ISIN
US02157Q1094
Symbol
ANRO

Alto Neuroscience Stock price

$6.89
+3.28 90.86% 1M
+5.04 272.43% 6M
+2.66 62.88% YTD
-3.30 32.38% 1Y
-9.11 56.94% 3Y
-9.11 56.94% 5Y
-9.11 56.94% 10Y
-9.11 56.94% 20Y
NYSE, Closing price Fri, Oct 03 2025
+2.48 56.24%
ISIN
US02157Q1094
Symbol
ANRO
Industry

Key metrics

Basic
Market capitalization
$186.6m
Enterprise Value
$61.1m
Net debt
positive
Cash
$147.6m
Shares outstanding
27.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.5
Financial Health
Equity Ratio
85.3%
Return on Equity
-40.6%
ROCE
-46.9%
ROIC
-
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-69.6m | $-80.3m
EBIT
$-70.2m | $-77.0m
Net Income
$-64.9m | $-70.1m
Free Cash Flow
$-56.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
0.5% | -17.9%
EBIT
0.4% | -12.2%
Net Income
1.4% | -14.1%
Free Cash Flow
0.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.4
FCF per Share
$-2.1
Short interest
7.7%
Employees
76
Rev per Employee
$0.0
Show more

Is Alto Neuroscience a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Alto Neuroscience Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Alto Neuroscience forecast:

13x Buy
87%
2x Hold
13%

Analyst Opinions

15 Analysts have issued a Alto Neuroscience forecast:

Buy
87%
Hold
13%

Financial data from Alto Neuroscience

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 23 23
36% 36%
-
- Research and Development Expense 47 47
12% 12%
-
-70 -70
0% 0%
-
- Depreciation and Amortization 0.63 0.63
9% 9%
-
EBIT (Operating Income) EBIT -70 -70
0% 0%
-
Net Profit -65 -65
1% 1%
-

In millions USD.

Don't miss a Thing! We will send you all news about Alto Neuroscience directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alto Neuroscience Stock News

Neutral
GlobeNewsWire
one day ago
SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of Alto Neuroscience, Inc. (NYSE: ANRO) shareholders against certain of its officers and directors who may have breached the fiduciary duties they owed to the Company.
Neutral
Business Wire
one day ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #FastTrack--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ALTO-101 for the treatment of cognitive impairment assoc...
Neutral
GlobeNewsWire
15 days ago
Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Alto (ANRO) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in  Alto between February 2, 2024 and October 22, 2024 and would like to discuss your legal rights, call Bragar Eagel & Squire partner  Brandon Walker or Marion Passmore directly at (212) ...
More Alto Neuroscience News

Company Profile

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Los Altos, CA.

Head office United States
CEO Amit Etkin
Employees 76
Founded 2019
Website www.altoneuroscience.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today